Inventor · disambiguated record
Simon Edward Ward
Also filed as: WARD SIMON · WARD SIMON E · WARD SIMON EDWARD
25 granted patents·14 pending applications·92 citations·filing 1998–2025
94Inventor score
Files withGLAXO GROUP LTD14UNIV COLLEGE CARDIFF CONSULTANTS LTD6JANSSEN PHARMACEUTICALS INC4VERNALIS RES LTD4ANDREOTTI DANIELE1
Top patents by PatentIndex Score
39 records- 0192US9981950B2Triazoles as NR2B receptor inhibitorsJANSSEN PHARMACEUTICALS INC·Filed 2015·Granted May 29, 2018·17 cites·28 claims
- 0291US10323021B2Triazoles as NR2B receptor inhibitorsJANSSEN PHARMACEUTICALS INC·Filed 2018·Granted Jun 18, 2019·13 cites·32 claims
- 0389US10155727B2PyrazolesJANSSEN PHARMACEUTICALS INC·Filed 2015·Granted Dec 18, 2018·15 cites·32 claims
- 0482US6583156B14-Quinolinemethanol derivatives as purine receptor antagonists (1)VERNALIS RES LTD·Filed 1999·Granted Jun 24, 2003·33 cites·26 claims
- 0577US7642256B2Compounds which potentiate AMPA receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2008·Granted Jan 5, 2010·2 cites·4 claims
- 0676US11298345B2Compounds that modulates AMPA receptor functionUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2019·Granted Apr 12, 2022·1 cites·23 claims
- 0774US2025375432A1Compounds that modulates ampa receptor functionUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2025·Application pending·0 cites
- 0872US11186567B2AMPA receptor potentiatorsUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2018·Granted Nov 30, 2021·1 cites·20 claims
- 0972US7592346B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2008·Granted Sep 22, 2009·1 cites·25 claims
- 1071US12383540B2Compounds that modulates AMPA receptor functionUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2022·Granted Aug 12, 2025·0 cites·75 claims
- 1171US7790758B2Compounds which potentiate glutamate receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2006·Granted Sep 7, 2010·2 cites·15 claims
- 1267US7741351B2Compounds which potentiate glutamate receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2005·Granted Jun 22, 2010·1 cites·14 claims
- 1366US7732600B2Quinoline and quinazoline derivatives having affinity for 5HT1-type receptorsGLAXO GROUP LTD·Filed 2009·Granted Jun 8, 2010·0 cites·4 claims
- 1461US7214674B2Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptorsGLAXO GROUP LTD·Filed 2003·Granted May 8, 2007·1 cites·12 claims
- 1561US6531511B12-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmissionVERNALIS RES LTD·Filed 2000·Granted Mar 11, 2003·2 cites·27 claims
- 1659US9115132B2Tetrazole compounds as calcium channel blockersBESWICK PAUL·Filed 2011·Granted Aug 25, 2015·1 cites·19 claims
- 1759US7566735B2Compounds which potentiate AMPA receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2007·Granted Jul 28, 2009·0 cites·4 claims
- 1857US7572819B2Compounds which potentiate glutamate receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2007·Granted Aug 11, 2009·0 cites·10 claims
- 1957US2024300936A1Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agentsAVELOS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2051US8093249B2Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivativesHEER JAG PAUL·Filed 2009·Granted Jan 10, 2012·0 cites·23 claims
- 2151US2010204273A1Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type ReceptorsGLAXO GROUP LTD·Filed 2010·Application pending·0 cites
- 2250US2024425491A1Heteroaryl compounds useful in the treatment of cognitive disordersUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2022·Application pending·0 cites
- 2349US7618969B2Compounds which potentiate glutamate receptor and uses thereof in medicineGLAXO GROUP LTD·Filed 2005·Granted Nov 17, 2009·0 cites·32 claims
- 2448US2025197368A12-oxo-dihydroquinoline-3-carboxamide derivatives as gaba type a receptor modulatorsUNIV COLLEGE CARDIFF CONSULTANTS LTD·Filed 2021·Application pending·0 cites
- 2547US2003130354A11-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmissionVERNALIS RES LTD·Filed 2002·Application pending·0 cites
- 2647US2009076032A1Derivatives of 18Beta-Glycyrrhetinic AcidWARD SIMON·Filed 2008·Application pending·0 cites
- 2744US8173820B2Compounds which potentiate the AMPA receptor and uses thereof in medicineBERTHELEME NICOLAS·Filed 2008·Granted May 8, 2012·0 cites·9 claims
- 2844US2009221643A14-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophreniaTHEWLIS KEVIN MICHAEL·Filed 2007·Application pending·0 cites
- 2943US7244726B2Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapyGLAXO GROUP LTD·Filed 2003·Granted Jul 17, 2007·0 cites·11 claims
- 3042US2005176724A1Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptorsFiled 2003·Application pending·0 cites
- 3142US2007270471A1Compounds Which Potentiate Glutamate Receptor and Uses Thereof in MedicineGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
- 3241USRE49517EPyrazolesJANSSEN PHARMACEUTICALS INC·Filed 2015·Granted May 2, 2023·0 cites·32 claims
- 3341US2005107410A1Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disordersFiled 2003·Application pending·0 cites
- 3440US9750719B2Tetrazole compounds as calcium channel blockersCONVERGENCE PHARMACEUTICALS·Filed 2015·Granted Sep 5, 2017·0 cites·18 claims
- 3540US2008255144A1Acylated Piperidines as Glycine Transporter InhibitorsGLAXO GROUP LTD·Filed 2006·Application pending·0 cites
- 3640US2009270510A1Glycine transport inhibitorsGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
- 3739US2009170902A1Compounds which potentiate glutamate receptor and uses thereof in medicineANDREOTTI DANIELE·Filed 2007·Application pending·0 cites
- 3837US8933132B2Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockersNORTON DAVID·Filed 2012·Granted Jan 13, 2015·0 cites·13 claims
- 3933US6500866B11-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmissionVERNALIS RES LTD·Filed 1998·Granted Dec 31, 2002·2 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Simon Edward Ward files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →